Bicycle Therapeutics PLC
1 day chart
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Buy US stocks in Australia starting with BCYC. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in BCYC
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.